OSIRIS THERAPEUTICS, INC.

Delayed Nasdaq  - 
0.000000 USD    0.00%
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société OSIRIS THERAPEUTICS, INC.
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Ther..
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
2019Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OS..
PR
2019ALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.
PR
2019OSIRIS THERAPEUTICS, INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout
BU
2019OSIRIS THERAPEUTICS : Smith & Nephew expands in high growth regenerative medicine market t..
PR
2019Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
GL
2019HAGENS BERMAN : Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to ..
BU
2019OSIRIS THERAPEUTICS : Hagens Berman Notifies Osiris Therapeutics, Inc. Investors of Class ..
BU
2018Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief..
GL
2018Osiris Therapeutics, Inc Reports Third Quarter 2018 Results
GL
2018Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
GL
2017Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
GL
2017Osiris Therapeutics, Inc. Provides Update on Audit of 2015 and 2016 Financial Statement..
GL
2017Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrob..
GL
2017Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including..
GL
2017Osiris Announces a Peer-Reviewed Publication Reporting the Use of Placental Membranes f..
GL
2017Osiris Appoints Linda Palczuk to serve as its President & CEO
GL
2017OSIRIS ANNOUNCES ELECTRONICALLY AVAI :   Open Surgical Implantation of a Viable Cryopreser..
GL
2017Osiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tiss..
GL
2017Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including..
GL
2017Osiris Therapeutics Announces Change in its Board of Directors
GL
2017Osiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient ..
GL
2017Osiris Therapeutics, Inc. Completes Restatement of 2014 Financial Statements
GL
2017Osiris Receives Notice of Delisting from NASDAQ
GL
2017Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors
GL
2017Osiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human..
GL
2017Osiris Therapeutics Announces Scientific Manuscript Reporting Antimicrobial Properties ..
GL
2016Osiris Provides Update Regarding NASDAQ Listing Matters
GL
2016Peer-reviewed Publication on the use of Grafix® in High-Risk Peripheral Arterial Diseas..
GL
2016Osiris Provides Update Regarding NASDAQ Listing Matters
GL
2016Osiris Therapeutics, Inc. Reports Preliminary 2014 and 2015 Revenue and Anticipated 201..
GL
2016OSIRIS THERAPEUTICS : Grafix® Cost Comparative Manuscript Reporting Wound Care Cost Reduct..
PU
2016OSIRIS THERAPEUTICS : Peer-reviewed Publication on the use of Grafix® Prime for Outpatient..
PU
2016Peer-reviewed Publication on the use of Grafix® Prime for Outpatient Management of Comp..
GL
2016Grafix® Cost Comparative Manuscript Reporting Wound Care Cost Reduction is Available El..
GL
2016Osiris to Present Clinical and Scientific Studies at Desert Foot 2016
GL
2016Net Health and Osiris Therapeutics Announce the Broad Availability of Grafix® to Wound ..
GL
2016Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Of..
GL
2016Osiris to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care (..
GL
2016Osiris Therapeutics to Present at 2016 Cell & Gene Meeting on the Mesa
GL
2016Osiris Provides Update Regarding NASDAQ Listing Status
GL
2016Osiris Provides Update Regarding NASDAQ Listing Matters
GL
2016Grafix® Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds wi..
GL
2016Khang & Khang LLP Announces an Investigation of Claims against Osiris Therapeutics, Inc..
BU
2016Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Secu..
BU
2016Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
PR
2016Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
BU
2016OSIRIS THERAPEUTICS : Provides Update Regarding NASDAQ Listing Matters
BU
2016OSIRIS THERAPEUTICS : to Present at the 26th European Wound Management Association Confere..
BU
2016OSIRIS THERAPEUTICS : Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix ..
PU
2016OSIRIS THERAPEUTICS : Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix ..
BU
2016OSIRIS THERAPEUTICS : to Present 15 Advanced Clinical and Scientific Abstracts
BU
2016OSIRIS THERAPEUTICS : Announces Further Expansion of Grafix Commercial Coverage
BU
2016OSIRIS THERAPEUTICS : Announces Receipt of Deficiency Letter from NASDAQ
BU
2016OSIRIS THERAPEUTICS : to Present at the 4th Annual Cell and Gene Therapy Investor Day
BU
2016OSIRIS THERAPEUTICS : Provides an Update on a Clinical Review by Blue Cross Blue Shield As..
BU
2016OSIRIS THERAPEUTICS : Faruqi & Faruqi, LLP : is Investigating Osiris Therapeutics, Inc. (O..
PR
2016OSIRIS THERAPEUTICS : Grafix Demonstrates Positive Clinical Outcomes in Chronic Complex Wo..
BU
2016OSIRIS THERAPEUTICS : Confirms Dwayne Montgomery, as President and Chief Executive Officer..
BU
2016OSIRIS THERAPEUTICS : Announces Leadership Transition
BU
2016OSIRIS THERAPEUTICS : Announces 100% Medicare Coverage for Grafix
BU
2016OSIRIS THERAPEUTICS : Responds to Statements about the Company Recently Posted to Several ..
BU
2016OSIRIS THERAPEUTICS : January 22 Deadline Alert: Law Offices of Howard G. Smith Reminds Os..
BU
2016OSIRIS THERAPEUTICS : Provides Update on Coverage for Grafix®
BU
2015OSIRIS THERAPEUTICS (OSIR) MISLED SH : Osiris Therapeutics, Inc. (OSIR) Misled Shareholder..
BU
2015SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action A..
PR
2015OSIRIS THERAPEUTICS : Pomerantz Law Firm Investigates Claims On Behalf of Osiris Therapeut..
PR
2015OSIRIS THERAPEUTICS : to Present at the 27th Annual Piper Jaffray Healthcare Conference
BU
2015OSIRIS THERAPEUTICS : Law Offices of Howard G. Smith : Commences Investigation on Behalf o..
BU
2015OSIRIS THERAPEUTICS : IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces an Ongoing In..
BU
2015OSIRIS THERAPEUTICS : IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces an Ongoing In..
BU
2015OSIRIS THERAPEUTICS : Robbins Arroyo LLP : Is Investigating the Officers and Directors of ..
BU
2015OSIRIS THERAPEUTICS : Wolf Popper LLP : Announces Investigation on Behalf of Investors in ..
PR
1  2  3  4Next